Diplomat Pharmacy (DPLO) Tops Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- S&P, Nasdaq end lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil slides on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
- Ovintiv adds 41,000 acres in Permian and Montney deals
Leerink Partners Raises Price Target on Diplomat Pharmacy (DPLO) to $36 Following 1Q Beat
May 10, 2016 9:00 AM EDTLeerink Partners reiterated an Outperform rating on Diplomat Pharmacy (NYSE: DPLO), and raised the price target to $36.00 (from $35.00), following the company's 1Q earnings report. DPLO reported total revenue of $996M, well ahead of consensus of $982.8M. The company also had a strong EPS... More
